Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

BusinessWeek October 21, 2010 Jesse Drucker	The Tax Haven That's Saving Google Billions Google uses a complicated structure to send most of its overseas profits to tax havens, keeping its corporate rate at a super-low 2.4 percent.
BusinessWeek March 17, 2011 Coy & Drucker	Apple, Google May Profit on a Tax Holiday Those companies and others say they'll bring home billions in earnings -- but only if they get a big tax break.
CFO April 1, 2007 Helen Shaw	Transfer Students As countries ratchet up their regulatory oversight, experts say companies should treat transfer pricing as a distinct category of risk.
CFO March 1, 2004 Ronald Fink	Haven or Hell? The IRS wants to crack down on multinational corporations that transfer U.S. intellectual property to tax havens.
The Motley Fool October 18, 2006 Brian Lawler	Seeing the Forest Through the Trees Underappreciated Forest Labs continues its trend of strong growth. Trading at roughly 20 times its forward earnings guidance even with a much higher level of R&D spending, here is a company that investors shouldn't lose sight of amidst the rest of the trees.
The Motley Fool January 17, 2006 Stephen D. Simpson	Forest Labs: Is Different Better? Forest isn't your typical pharmaceutical company, and that's both its boon and its bane for investors.
Reason Aug/Sep 2009 Veronique de Rugy	Destroying Jobs in Order to Save Them: Obama's Corporate Tax "Reforms" Make a Bad Situation Worse. Instead of making the corporate tax system worse, why not reform it? Why not avoid old protectionist tricks such as Buy American provisions and instead let U.S. firms compete abroad without the chains of the U.S. tax code?
The Motley Fool January 18, 2012 Sean Williams	This Company is Quickly Approaching the Patent Cliff Earnings exceed expectations at drug manufacturer Forest Laboratories, but worries about future sales mount.
CFO February 1, 2011 Marie Leone	No Taxation Without Ramifications The Bush tax-cut debate may have captured the headlines leading up to the new year, but there are at least half a dozen lower-profile tax issues that CFOs should keep tabs on, with more to come as the year unfolds.
The Motley Fool April 24, 2007 Ryan Fuhrmann	Mixed Foliage at Forest Labs Here's what to look for as Forest Labs prepares for a big loss. Investors, take note.
The Motley Fool October 22, 2009 Robert Steyer	Nibbles Here and There at Forest Labs Forest Laboratories banks on its usual strategy of licensing and collaboration to offset generic-drug threats.
The Motley Fool October 5, 2004 W.D. Crotty	Lots of Profits in This Forest Drug manufacturer Forest Laboratories, down sharply from its high, offers value and growth.
The Motley Fool September 12, 2006 Brian Lawler	Glaxo's Big Tax Bill The pharmaceutical finally decided to pay up and settle its long-running tax dispute with the IRS for $3.1 billion.
The Motley Fool January 10, 2007 Rich Duprey	Foolish Forecast: Greener Forest Labs The pharmaceutical firm stands tall against competition. When the company releases its third-quarter 2007 financials, investors shouldn't have to reach for their medicine chest.
The Motley Fool April 19, 2005 Stephen D. Simpson	Does Forest Have the Blues? Hugely dependent on a single drug, Forest is in a precarious position. Though the next couple of years could be a little hairier than what most pharma investors are normally accustomed to, Forest is worth a look.
The Motley Fool July 18, 2006 Stephen D. Simpson	Survival of the Forest New products and a favorable patent ruling give Forest Labs a boost. Investors, this stock remains one to watch.
The Motley Fool July 14, 2006 Stephen D. Simpson	The Diverging Fortunes of Forest and Teva If a patent ruling holds up, Forest's prospects are much stronger. Unfortunately, the easy money has long since been made in Forest and today's announcement will almost certainly mean another big jump in the stock price.
The Motley Fool April 16, 2008 Brian Orelli	Forest Labs' Race Against the Clock Investors don't seem to like Forest Labs' ambitious plans for research and development.
CFO July 1, 2002 Tim Reason	Love It and Leave It? Will the outcry over inversions change the way overseas income is taxed?
CFO September 1, 2009 Alix Stuart	Transfer Pricing: A World of Pain China, India, and other once tax-friendly domains look to squeeze U.S.-based multinationals on sales between subsidiaries.
The Motley Fool October 18, 2005 Stephen D. Simpson	Forest Labs' Clear-Cut Woes Patent litigation, generic competition, and drug development troubles nibble away at this pharmaceutical. Investors, take note.
The Motley Fool January 19, 2007 Billy Fisher	The Best Drug Stock for 2007: Forest Laboratories Management shows confidence in its company, which has been busy with expansion. Investors, take note.
The Motley Fool May 1, 2006 Stephen D. Simpson	Short-Term Fears Chip Into Forest Investors may be getting a second chance at unconventional Forest Labs. With the stock having pulled back, it's now very close to a tantalizing price.
BusinessWeek June 12, 2006 Gene G. Marcial	New Growth At Forest? Forest Laboratories has been a drag among drugmakers.
Chemistry World November 22, 2010 Akshat Rathi	Irish drug industry fears bailout tax terms Any increase in Ireland's corporation tax rate as part of a financial bailout could hurt the country's rapidly expanding pharmaceutical industry, currently its largest contributor to corporation tax.
The Motley Fool January 16, 2008 Brian Orelli	Forest Labs Not Down -- Yet Double-digit revenue growth is the highlight of a good quarter for Forest Labs, but the company will need a lot more than one solid quarter to get its stock growing again.
The Motley Fool September 1, 2004 W.D. Crotty	A Pall Falls Over Forest One of Forest Labs' Alzheimer's drugs fails in phase 3 trials. For investors willing to take the political risk, today's drug news has taken a battered stock, with a great balance sheet, to very reasonable price levels.
BusinessWeek September 27, 2004 Kerry Capell	How Dublin Keeps Big Pharma Happy By providing cheap yet educated workers and giving tax breaks to big investors, the Irish have turned their country into a major drug manufacturing center.
BusinessWeek November 24, 2010 Heatley & Gotkine	Battered Ireland Clings to Its Low Taxes Though Ireland needs $115 billion, it says its 12.5 percent corporate tax rate is "non-negotiable"
The Motley Fool February 22, 2011 Brian Orelli	Timber! Clinical Data Falls. Forest Labs cuts down Clinical Data. Clinical Data announced today that it agreed to be purchased by Forest Labs for $30 per share.
Pharmaceutical Executive June 1, 2013	Country Report: Ireland Ireland has been a pharma industry darling since the 1960s, when a then-newly established IDA targeted the sector as a strategic area for development. Today, the numbers are eye catching.
The Motley Fool June 29, 2011 Isac Simon	Forest Oil's Unique Advantage in the Natural Gas Market Ambitious plans and a sound business model should help this company reap huge returns.
The Motley Fool January 27, 2009 Robert Steyer	Another Angle for Fibromyalgia In the past 18 months, the FDA has approved three drugs that can be used to treat the disease. Which pharma companies will benefit?
The Motley Fool October 16, 2007 Billy Fisher	Forest Labs Isn't Out of the Woods Yet The drugmaker's Q2 profit falls, but the company raises its full-year forecast.
The Motley Fool March 31, 2005 Stephen D. Simpson	Another "No" for Lexapro This latest FDA setback shouldn't hurt Forest Labs much, and the shares look like a bargain.
The Motley Fool November 29, 2005 Stephen D. Simpson	Forest Seeds Future Growth A new deal with long-term benefits signals that the pharmaceutical remains credible. Patient investors may yet find this stock worth some due diligence.
The Motley Fool December 19, 2007 Brian Orelli	New Beta Blocker on the Crowded Street Forest and Mylan receive FDA approval for Bystolic. Investors, take note.
CFO July 15, 2008 Alix Stuart	Don't Mess with the IRS The IRS is taking companies to court more often, and winning. Is it time to rethink your tax position?
The Motley Fool December 3, 2007 Brian Orelli	Nebivolol's Almost Approvable Letter Forest and Mylan get an approvable letter for Nebivolol.
The Motley Fool October 30, 2007 Billy Fisher	Is Forest Labs' Nebivolol Ready for Prime Time? Shareholders of the pharmaceutical company have been looking for a way to boost their floundering stock. The FDA's likely approval of hypertension drug Nebivolol may be the answer.
CFO June 1, 2011 Janet Kersnar	Back on the Map Ireland's domestic economy may be in shambles, but expansion-minded U.S. firms see plenty of opportunity there.
The Motley Fool January 21, 2004 Alyce Lomax	Forest Labs' High Hopes Alzheimer's treatment drug Namenda seems to be Forest's strong suit.
Bank Systems & Technology March 15, 2009 Orla O'Sullivan	Irish Banks Reeling From Bursting of Property Bubble Declining property values have sent Ireland's banking industry -- and economy -- into a downward spiral. But bank consolidation and automation efforts may help the small island's financial technology sector regain its footing.
Pharmaceutical Executive September 1, 2005 Bill Trombetta	2005 Industry Audit Who's really on top in the pharmaceutical industry?
The Motley Fool July 19, 2005 Stephen D. Simpson	A Clearing in the Forest? Despite so-so results, the biotech stock's slide may finally be over.
The Motley Fool September 11, 2007 Brian Orelli	Teva Spending Plenty of Time in Court Three patent disputes in one week keeps the lawyers busy: Teva and Novartis have been locked in dispute over Novartis' Famvir tablets... Teva and Forest spar over patents for Lexapro... Teva and Wyeth argue over Protonix...
Chemistry World August 7, 2012 Anthony King	Irish pharma exports tumble Irish pharma exports to the US declined 30% in the first six months of this year as a clatter of blockbuster drugs made in Ireland, such as Lipitor (atorvastatin), came off patent.
The Motley Fool November 30, 2011 Isaac Pino	I Was Wrong About Ireland The Celtic Tiger economy exited as quickly as it arrived on the Emerald Isle.
InternetNews July 1, 2004 Colin C. Haley	Lucent Extends R&D Roots The company's Bell Labs partners with Irish government on research center in Dublin.
Pharmaceutical Executive September 1, 2006 Bill Trombetta	Industry Audit This fifth annual report dives deep into the numbers and comes up with the pharmaceutical industry's true top performers.